Akumentis Healthcare first synthetic CBD for epilepsy

1 Star2 Stars3 Stars4 Stars5 Stars (No Ratings Yet)
Medlarge Featured, Latest, Pharma News
first synthetic CBD for epilepsy

Akumentis Healthcare Limited, pharma major, has launched Clasepi – DCGI-approved prescription cannabidiol (CBD] specifically formulated to address seizures linked with Lennox-Gastaut Syndrome (LGS), Dravet Syndrome, or Tuberous Sclerosis Complex (TSC) in patients aged 1 year and older.

Clasepi marks a development as the first synthetic CBD product of its kind to be made available in India.The product with THC content below 0.1%, stands out for its non-psychotropic nature. Clinical studies have demonstrated Clasepi efficacy in reducing seizures, especially in cases where conventional antiseizure medications have proven ineffective.

“Patients grappling with a rare and severe form of epilepsy often endure a protracted journey to obtain an accurate diagnosis, tolerating nearly five years of uncontrolled seizures from the onset. In certain instances, individuals may enter adulthood without a precise diagnosis, despite wrestling with conditions like LGS, DS, or TSC”, said Kanishk Jain, Executive Director, Akumentis. 

As per WHO estimation, epilepsy constitutes a considerable portion of the global disease burden, affecting approximately 50 million people worldwide, with 20% of patients residing in India. WHO asserts that up to 70% of individuals with epilepsy could achieve seizure freedom with the proper use of progressive anti-seizure medicines. Beyond the seizures themselves, pervasive myths and discrimination surrounding epilepsy create additional hurdles for affected individuals and their families. In India, a sizable number of patients suffers from Lennox-Gastaut Syndrome (LGS), Dravet Syndrome, or Tuberous Sclerosis Complex (TSC) for whom doctors will find clasepi as a new armamentarium in epilepsy therapy protocol.

Accentuating the Akumentis commitment to advancing healthcare solutions, Pradeep Patni, Chief Executive Officer at Akumentis, added, “Akumentis is always working to find better cures and create innovative products in various therapy areas. We actively plan for the future and strive to be pioneers in our field. Our organization is constantly adapting and evolving, aiming to raise awareness and make a positive impact for better healthcare. Clasepi is carefully designed to meet the specific needs of conditions, recognizing the limitations of traditional anti-epilepsy medicines.”